We all see nature's wonders every day,whether it be a plant that moves or a sunset that reaches with pink fingers into a sky of deep blue.The key to true curiosity is pausing to ponder the causes.What makes a sky blue or a sunset pink or a leaf of sleeping grass curl?
(查看原文)
Women in science tend to be shy about promoting themselves, and that has serious costs. A study in 2019 of more than six million articles with women as the principal author showed that they are less likely to use self promotional terms,such as“novel" and“unique” and
"unprecedented," to describe their findings. The trend is especially true for articles in the most prestigious journals, which almost by definition feature research that is groundbreaking. In the highest-impact journals that publish the most important cutting-edge research, women are 21 percent less likely to use positive and self-promotional words in describing their work. Partly as a result, their papers are cited approximately 10 percent less frequently. (查看原文)
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. –
– Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment –
– Multiple authorized treatment centers activated –
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older ... (查看原文)
